Puma Biotechnology, Inc. NASDAQ:PBYI

Founder-led company

Puma Biotechnology stock price today

$4.99
+1.91
+62.01%
Financial Health
0
1
2
3
4
5
6
7
8
9

Puma Biotechnology stock price monthly change

-14.21%
month

Puma Biotechnology stock price quarterly change

-14.21%
quarter

Puma Biotechnology stock price yearly change

-29.03%
year

Puma Biotechnology key metrics

Market Cap
134.50M
Enterprise value
168.08M
P/E
13.23
EV/Sales
0.73
EV/EBITDA
8.01
Price/Sales
0.57
Price/Book
6.01
PEG ratio
0.13
EPS
0.32
Revenue
226.62M
EBITDA
39.64M
Income
15.37M
Revenue Q/Q
-17.07%
Revenue Y/Y
-3.60%
Profit margin
0%
Oper. margin
13.47%
Gross margin
75.84%
EBIT margin
13.47%
EBITDA margin
17.49%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Puma Biotechnology stock price history

Puma Biotechnology stock forecast

Puma Biotechnology financial statements

Puma Biotechnology, Inc. (NASDAQ:PBYI): Profit margin
Jun 2023 54.56M 2.12M 3.9%
Sep 2023 56.11M 5.79M 10.33%
Dec 2023 72.17M 12.26M 17%
Mar 2024 43.76M -4.81M -11%
Puma Biotechnology, Inc. (NASDAQ:PBYI): Analyst Estimates
2025 225.05M 15.1M 6.71%
2026 229.8M 15.55M 6.77%
2027 205M -7.13M -3.48%
2028 200M -11.88M -5.94%
  • Analysts Price target

  • Financials & Ratios estimates

Puma Biotechnology, Inc. (NASDAQ:PBYI): Earnings per share (EPS)
2024-02-29 0.3 0.26
Puma Biotechnology, Inc. (NASDAQ:PBYI): Debt to assets
Jun 2023 200494000 170.09M 84.84%
Sep 2023 203605000 164.86M 80.97%
Dec 2023 230528000 177.08M 76.82%
Mar 2024 214149000 163.16M 76.19%
Puma Biotechnology, Inc. (NASDAQ:PBYI): Cash Flow
Jun 2023 3.29M -4.68M 0
Sep 2023 10.61M 11.17M 0
Dec 2023 10.45M -8.17M 0
Mar 2024 11.24M -19.08M 0

Puma Biotechnology alternative data

Puma Biotechnology, Inc. (NASDAQ:PBYI): Employee count
Aug 2023 192
Sep 2023 192
Oct 2023 192
Nov 2023 192
Dec 2023 192
Jan 2024 192
Feb 2024 192
Mar 2024 185
Apr 2024 185
May 2024 185
Jun 2024 185
Jul 2024 185

Puma Biotechnology other data

60.21% -5.89%
of PBYI is owned by hedge funds
27.31M -588.22K
shares is hold by hedge funds

Puma Biotechnology, Inc. (NASDAQ:PBYI): Insider trades (number of shares)
Period Buy Sel
Nov 2023 0 25000
Jan 2024 0 86125
Jun 2024 0 96900
Jul 2024 0 34580
Transaction Date Insider Security Shares Price per share Total value Source
Sale
NOUGUES MAXIMO F officer: Chief Fi.. Common Stock 5,295 $3.27 $17,309
Sale
LUDWIG JEFFREY JEROME officer: Chief Co.. Common Stock 6,051 $3.27 $19,781
Sale
HUNT DOUGLAS M officer: See Remarks
Common Stock 4,349 $3.27 $14,217
Sale
AUERBACH ALAN H director, 10 perc.. Common Stock 18,885 $3.27 $61,735
Sale
WILSON TROY EDWARD director Common Stock 27,000 $3.33 $89,910
Sale
WILSON TROY EDWARD director Common Stock 27,000 $3.33 $89,910
Sale
STUGLIK BRIAN M director
Common Stock 9,900 $3.39 $33,531
Sale
SENDEROWICZ ADRIAN director
Common Stock 27,000 $3.33 $89,829
Sale
MOYES JAY M director
Common Stock 22,000 $3.34 $73,458
Sale
DORVAL ALLISON director
Common Stock 11,000 $3.37 $37,092
Insider Compensation
Mr. Alan H. Auerbach (1970) Founder, Chairman, Pres, Chief Executive Officer & Sec. $5,690,000
Mr. Jeffrey Jerome Ludwig (1966) Chief Commercial Officer $4,610,000
Mr. Douglas Hunt B.Sc., FRAPS (1965) Senior Vice President of Regulatory Affairs, Medical Writing & Project Management
$2,140,000
Mr. Maximo F. Nougues (1969) Chief Financial Officer & Principal Accounting Officer $1,630,000
Friday, 27 December 2024
zacks.com
Tuesday, 24 December 2024
zacks.com
zacks.com
zacks.com
Monday, 23 December 2024
businesswire.com
Monday, 16 December 2024
seekingalpha.com
Wednesday, 4 December 2024
businesswire.com
Thursday, 28 November 2024
zacks.com
Thursday, 21 November 2024
zacks.com
Friday, 8 November 2024
zacks.com
Thursday, 7 November 2024
seekingalpha.com
zacks.com
Tuesday, 5 November 2024
businesswire.com
Tuesday, 29 October 2024
globenewswire.com
Friday, 2 August 2024
zacks.com
Thursday, 1 August 2024
seekingalpha.com
zacks.com
businesswire.com
zacks.com
Tuesday, 23 July 2024
zacks.com
Thursday, 18 July 2024
businesswire.com
Tuesday, 2 July 2024
businesswire.com
Friday, 7 June 2024
businesswire.com
Monday, 3 June 2024
businesswire.com
Sunday, 2 June 2024
businesswire.com
Tuesday, 28 May 2024
businesswire.com
Friday, 24 May 2024
zacks.com
Thursday, 23 May 2024
businesswire.com
Friday, 3 May 2024
Zacks Investment Research
Thursday, 2 May 2024
Seeking Alpha
  • What's the price of Puma Biotechnology stock today?

    One share of Puma Biotechnology stock can currently be purchased for approximately $4.99.

  • When is Puma Biotechnology's next earnings date?

    Unfortunately, Puma Biotechnology's (PBYI) next earnings date is currently unknown.

  • Does Puma Biotechnology pay dividends?

    No, Puma Biotechnology does not pay dividends.

  • How much money does Puma Biotechnology make?

    Puma Biotechnology has a market capitalization of 134.50M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 3.35% to 235.64M US dollars. Puma Biotechnology earned 21.59M US dollars in net income (profit) last year or $0.26 on an earnings per share basis.

  • What is Puma Biotechnology's stock symbol?

    Puma Biotechnology, Inc. is traded on the NASDAQ under the ticker symbol "PBYI".

  • What is Puma Biotechnology's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Puma Biotechnology?

    Shares of Puma Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Puma Biotechnology's key executives?

    Puma Biotechnology's management team includes the following people:

    • Mr. Alan H. Auerbach Founder, Chairman, Pres, Chief Executive Officer & Sec.(age: 55, pay: $5,690,000)
    • Mr. Jeffrey Jerome Ludwig Chief Commercial Officer(age: 59, pay: $4,610,000)
    • Mr. Douglas Hunt B.Sc., FRAPS Senior Vice President of Regulatory Affairs, Medical Writing & Project Management(age: 60, pay: $2,140,000)
    • Mr. Maximo F. Nougues Chief Financial Officer & Principal Accounting Officer(age: 56, pay: $1,630,000)
  • Is Puma Biotechnology founder-led company?

    Yes, Puma Biotechnology is a company led by its founder Mr. Alan H. Auerbach.

  • How many employees does Puma Biotechnology have?

    As Jul 2024, Puma Biotechnology employs 185 workers.

  • When Puma Biotechnology went public?

    Puma Biotechnology, Inc. is publicly traded company for more then 13 years since IPO on 24 Apr 2012.

  • What is Puma Biotechnology's official website?

    The official website for Puma Biotechnology is pumabiotechnology.com.

  • Where are Puma Biotechnology's headquarters?

    Puma Biotechnology is headquartered at 10880 Wilshire Boulevard, Los Angeles, CA.

  • How can i contact Puma Biotechnology?

    Puma Biotechnology's mailing address is 10880 Wilshire Boulevard, Los Angeles, CA and company can be reached via phone at 424 248 6500.

Puma Biotechnology company profile:

Puma Biotechnology, Inc.

pumabiotechnology.com
Exchange:

NASDAQ

Full time employees:

185

Industry:

Biotechnology

Sector:

Healthcare

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

10880 Wilshire Boulevard
Los Angeles, CA 90024

CIK: 0001401667
ISIN: US74587V1070
CUSIP: 74587V107